CRDF
Cardiff Oncology, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.33
P/S
182.15
EV/EBITDA
-1.96
DCF Value
$0.01
FCF Yield
-35.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1890.4%
Operating Margin
-8256.3%
Net Margin
-7732.2%
ROE
-82.0%
ROA
-74.1%
ROIC
-105.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $243.0K | $-7.2M | $-0.11 |
| FY 2025 | $593.0K | $-45.9M | $-0.69 |
| Q3 2025 | $120.0K | $-11.3M | $-0.17 |
| Q2 2025 | $121.0K | $-13.9M | $-0.21 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.42
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.